To further elaborate the dependency of the anti-leukemic activity of daratumumab on CD38 expression in AML, we correlated the CD38 expression of primary AML cells under different culture conditions with the degree of reduction of AML cell growth in vitro (Fig. 2c). The gene discussed is CD38; the disease is acute myeloid leukemia.